Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds
CAMBRIDGE, Mass. — Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its
(Financial Post, 2025-12-12T21:55:53Z)